Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label extension study of oral ozanimod in moderate to severe active Crohn's disease
CTR20211116Phase 3Terminated
- Sponsor
- Celgene Corporation
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ozanimod in Crohn's disease, sponsored by Celgene Corporation. Started Dec 2021; status: terminated.
02
Drugs
ozanimod
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on CTR20211116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211116.